Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*						2. Issuer Name and Ticker or Trading Symbol Emergent BioSolutions Inc. [EBS]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Abdun-Nabi Daniel						(-) X	Directo	r		10% Ow	ner	
(Last) (First) (Middle) 2273 RESEARCH BLVD. SUITE 400						3. Date of Earliest Transaction (Month/Day/Year) 03/09/2010									Officer below)	(give title Presiden	ıt & (Other (specify below)		
(Street) ROCKVILLE MD 20850 (City) (State) (Zip)					4.	4. If Amendment, Date of Original Filed (Month/Day/Year)									Form f	or Joint/Group Filing (Check Applicable In filed by One Reporting Person In filed by More than One Reporting In filed by More than One Reporting				
		Tab	le I - Noi	n-Deri	vativ	e Se	curities	s Ac	quired,	Dis	oosed o	f, or B	enef	icially	/ Owned					
1. Title of Security (Instr. 3) 2. Transal Date (Month/D:						ear)	2A. Deemed Execution Date, f any Month/Day/Year)		Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)			a) or 4 and		es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) or (D) Pr		Price	Reported Transact (Instr. 3	ion(s)			insu. 4)	
Common Stock ⁽¹⁾ 03/09/						2010		A		22,145	5 (2)	1	\$0	42,295			D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,	4. Transa Code (8)		of		6. Date Exercisa Expiration Date (Month/Day/Yea		of Securities		ities ng /e Sec	urity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisab		expiration Date	Title	or Nu of	nount mber ares						
Employee Stock Option (right to	\$15.91	03/09/2010			A		44,291		(3)	0	3/10/2017	Common Stock	¹ 44	,291	\$0	44,291	1	D		

Explanation of Responses:

- 1. Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan.
- 2. These restricted stock units vest in three equal annual installments beginning on the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
- 3. Exercisable in three equal installments on March 9, 2011, March 9, 2012 and March 9, 2013

Remarks:

/s/R. Don Elsey, attorney-in-

03/11/2010

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.